bp102
Small moleculeexperimental
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
14
Phase 3
3
Phase 4
0
Earliest trial started Jan 25, 2018 (NCT05169801)
Timeline
Indications
Mechanism of action
- NeprilysinINHIBITOR
MME inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07268040 | Phase 2 | Dec 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT07241767 | Phase 2 | Nov 12, 2025 | Hengrui Therapeutics, Inc. |
| NCT07028281 | Phase 2 | Jul 8, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07061210 | Phase 2 | Jul 1, 2025 | Fudan University |
| NCT06679673 | Phase 2 | Dec 31, 2024 | Fudan University |
| NCT06373133 | Phase 1/Phase 2 (Phase 2) | May 1, 2024 | Sichuan University |
| NCT05749588 | Phase 2 | Mar 30, 2023 | Fudan University |
| NCT05179239 | Phase 3 | Feb 26, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04974957 | Phase 2 | Aug 30, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04856787 | Phase 2/Phase 3 (Phase 3) | Jun 22, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04856774 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT04395989 | Phase 2 | May 15, 2020 | Fudan University |
| NCT03666728 | Phase 2 | Oct 1, 2018 | Hengrui Therapeutics, Inc. |
| NCT03645876 | Phase 2 | Sep 30, 2018 | Hengrui Therapeutics, Inc. |
| NCT05169801 | Phase 3 | Jan 25, 2018 | Hengrui Therapeutics, Inc. |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2018 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 5 | 5 | 2 | 2021 |
| Fudan University | Academic/Hospital | 4 | 4 | 1 | 2020 |
| Sichuan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1